The company’s research centers on the LRRK2–RAB10 pathway, which regulates how cells manage stress and inflammation. By inhibiting LRRK2, HT-4253 aims to restore microglial function and reduce tau phosphorylation, key markers of neurodegeneration. David Bearss, CEO of Halia Therapeutics, stated that preclinical models confirm the drug effectively engages its target, dampening pro-inflammatory cytokine secretion and improving phagocytic function in microglia.

Beyond lab results, Halia is moving into human trials through a strategic Phase 2a study. This initiative utilizes population-scale genomics in the UAE to identify cognitively normal APOE4 carriers. Candidates are screened using the PrecivityAD2 blood test to detect early amyloid pathology. Participants in the 48-week study will receive once-daily doses of HT-4253, with researchers tracking blood-based biomarkers to determine if the intervention can successfully delay the onset of Alzheimer’s.